Genprex

News

Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Gene therapies and immunotherapies are two different types of treatment….

Read More

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

A direct target of miR-138, TUSC2 mimics miR-138 knockdown

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 11, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options….

Read More

Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 5, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the H.C. Wainwright 21stAnnual Global Investment Conference on September 9, 2019 in New York City.

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be available for one-on-one meetings. …

Read More

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 3, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website….

Read More

Pfizer’s Half-Billion-Dollar Manufacturing Facility Demonstrates Commitment to Gene Therapy

Pfizer recently announced its plans to invest $500 million into its Sanford gene therapy manufacturing operations. This expansion would create 300 new jobs, and Pfizer’s biopharmaceuticals group president noted the company “passionately believes in gene therapy.”

This passion for gene therapy, which is seemingly shared with other large biopharma companies, is leading to substantial commitments of resources to gene therapy….

Read More

Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference

AUSTIN, Texas & CAMBRIDGE, Mass.— (August 21, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4thAnnual Disruptive Growth Conference hosted by ReedSmith in New York City on September 4, 2019.

Genprex will present at the 4thAnnual Disruptive Growth Conference as follows:

Date: Wednesday, September 4, 2019

Time: 5:00-5:15 p.m….

Read More

Genprex Demonstrates Growth and Expansion Through Recent Achievements

Company’s recent performance sets path for future milestones, commercialization

AUSTIN, Texas & CAMBRIDGE, Mass.— (August 13,2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced recent achievements the company has completed as a part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex™ immunogene therapy, to commercialization….

Read More

Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

AUSTIN, Texas & CAMBRIDGE, Mass.— (August 6, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018….

Read More

Genprex Begins Next Phase of Drug Branding Program

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it has initiated the first phase of branding its lead drug candidate, Oncoprex™ immunogene therapy, and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.

Upon receiving feedback from the USAN Council, which is expected later this year, Genprex will submit its non-proprietary drug name selections to the World Health Organization for International Nonproprietary Names (INN) status….

Read More

A Potential NSCLC Treatment for Large Patient Populations

Today’s cancer treatment options are not one-size-fits-all. But Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based on a unique proprietary technology platform, is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies….

Read More